Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma

Cancer

Volumn 118, Issue 11, 2012, Pages 2858-2871

  Cao, Wei ^a,b   Feng, Zhien ^a,b   Cui, Zhibin ^a,b   Zhang, Chenping ^a,b   Sun, Zhaoyao ^b   Mao, Li ^a,c   Chen, Wantao ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Key Laboratory of Stomatology   (China)

^c UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

Author keywords

clinical outcome; cyclin D1; enhancer of zeste homolog 2; head and neck; prognostic predictor; squamous cell carcinoma

Indexed keywords

CYCLIN D1; MESSENGER RNA; TRANSCRIPTION FACTOR EZH2;

ADULT; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CYCLIN D1; DNA-BINDING PROTEINS; FEMALE; GENE SILENCING; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; TRANSCRIPTION FACTORS; TRANSFECTION; UP-REGULATION;

EID: 84861332826     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26575     Document Type: Article

References (42)

1. Mignogna MD, Fedele S, Lo Russo L,. The World Cancer Report and the burden of oral cancer. Eur J Cancer Prev. 2004; 13: 139-142.
2. Cabanillas R, Rodrigo JP, Astudillo A, Dominguez F, Suarez C, Chiara MD,. P53 expression in squamous cell carcinomas of the supraglottic larynx and its lymph node metastases: new results for an old question. Cancer. 2007; 109: 1791-1798.
3. Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol. 2007; 25: 2164-2170.
4. Weber A, Hengge UR, Stricker I, et al. Protein microarrays for the detection of biomarkers in head and neck squamous cell carcinomas. Hum Pathol. 2007; 38: 228-238.
5. Fischer CA, Kampmann M, Zlobec I, et al. p16 expression in oropharyngeal cancer: its impact on staging and prognosis compared with the conventional clinical staging parameters. Ann Oncol. 2010; 21: 1961-1966.
6. Simon JA,. Transcription. Sweet silencing. Science. 2009; 325: 45-46.
7. Ho L, Crabtree GR,. An EZ mark to miss. Cell. 2008; 3: 577-578.
8. Valk-Lingbeek ME, Bruggeman SW, Van Lohuizen M,. Stem cells and cancer: the Polycomb connection. Cell. 2004; 118: 409-418.
9. Vire E, Brenner C, Deplus R, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006; 439: 871-874.
10. Chen S, Bohrer LR, Rai AN, et al. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol. 2010; 12: 1108-1114.
11. Wei Y, Chen YH, Li LY, et al. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol. 2011; 13: 87-94.
12. Zeng X, Chen S, Huang H,. Phosphorylation of EZH2 by CDK1 and CDK2: a possible regulatory mechanism of transmission of the H3K27me3 epigenetic mark through cell divisions. Cell Cycle. 2011; 10: 579-583.
13. Varambally S, Dhanasekaran SM, Zhou M, et al. The Polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002; 419: 624-629.
14. Gong Y, Huo L, Liu P, et al. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome [published online ahead of print June 28, 2011]. Cancer. 2011.
15. Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K, Yokozaki H,. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci. 2006; 97: 484-491.
16. Kikuchi J, Kinoshita I, Shimizu Y, et al. Distinctive expression of the Polycomb group proteins Bmi1 Polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer. 2010; 116: 3015-3024.
17. He LR, Liu MZ, Li BK, et al. High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer. 2010; 127: 138-147.
18. Vekony H, Raaphorst FM, Otte AP, et al. High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma. J Clin Pathol. 2008; 61: 744-749.
19. Alajez NM, Shi W, Hui AB, et al. Enhancer of zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98 [serial online]. Cell Death Dis. 2010; 1: e85.
20. Kidani K, Osaki M, Tamura T, et al. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol. 2009; 45: 39-46.
21. Cao W, Younis RH, Li J, et al. EZH2 promotes malignant phenotypes and is a predictor of oral cancer development in patients with oral leukoplakia [published online ahead of print June 22, 2011]. Cancer Prev Res (Phila). 2011.
22. Zhou X, Zhang Z, Yang X, Chen W, Zhang P,. Inhibition of cyclin D1 expression by cyclin D1 shRNAs in human oral squamous cell carcinoma cells is associated with increased cisplatin chemosensitivity. Int J Cancer. 2009; 124: 483-489.
23. Cao W, Zhang ZY, Xu Q, et al. Epigenetic silencing of MAL, a putative tumor suppressor gene, can contribute to human epithelium cell carcinoma. Mol Cancer. 2010; 9: 296.
24. Choi JH, Song YS, Yoon JS, Song KW, Lee YY,. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer. APMIS. 2010; 118: 196-202.
25. Balasubramanian S, Adhikary G, Eckert RL,. The Bmi-1 Polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival. Carcinogenesis. 2010; 31: 496-503.
26. Shibata D,. Mutation and epigenetic molecular clocks in cancer. Carcinogenesis. 2011; 32: 123-128.
27. Taby R, Issa JP,. Cancer epigenetics. CA Cancer J Clin. 2010; 60: 376-392.
28. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002; 298: 1039-1043.
29. Martinez-Garcia E, Licht JD,. Deregulation of H3K27 methylation in cancer. Nat Genet. 2010; 42: 100-101.
30. Ding L, Erdmann C, Chinnaiyan AM, Merajver SD, Kleer CG,. Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res. 2006; 66: 4095-4099.
31. Kondo Y, Shen L, Cheng AS, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008; 40: 741-750.
32. Mao L, Hong WK, Papadimitrakopoulou VA,. Focus on head and neck cancer. Cancer Cell. 2004; 5: 311-316.
33. Izzo JG, Papadimitrakopoulou VA, Liu DD, et al. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst. 2003; 95: 198-205.
34. Fu ZJ, Ma ZY, Wang QR, et al. Overexpression of cyclin D1 and underexpression of p16 correlate with lymph node metastases in laryngeal squamous cell carcinoma in Chinese patients. Clin Exp Metastasis. 2008; 25: 887-892.
35. Umekita Y, Ohi Y, Sagara Y, Yoshida H,. Overexpression of cyclin D1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer. 2002; 98: 415-418.
36. Li H, Cai Q, Godwin AK, Zhang R,. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol Cancer Res. 2010; 8: 1610-1618.
37. Velichutina I, Shaknovich R, Geng H, et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood. 2010; 116: 5247-5255.
38. Zhao F, Chen Y, Zeng L, et al. Role of triptolide in cell proliferation, cell cycle arrest, apoptosis and histone methylation in multiple myeloma U266 cells. Eur J Pharmacol. 2010; 646: 1-11.
39. Karanikolas BD, Figueiredo ML, Wu L,. Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines. Prostate. 2010; 70: 675-688.
40. Aoki R, Chiba T, Miyagi S, et al. The Polycomb group gene product Ezh2 regulates proliferation and differentiation of murine hepatic stem/progenitor cells. J Hepatol. 2010; 52: 854-863.
41. Holland D, Hoppe-Seyler K, Schuller B, et al. Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein. Cancer Res. 2008; 68: 9964-9972.
42. Kim L, King T, Agulnik M,. Head and neck cancer: changing epidemiology and public health implications. Oncology. 2010; 24: 915-919.